Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

about

A biomechanical evaluation of femoroplasty under simulated fall conditions.Development of an animal fracture model for evaluation of cement augmentation femoroplasty: an in vitro biomechanical study.Low-dose risedronate sodium protects bone cells after abrupt oestrogen withdrawal.

P2860

Q33618852-E5DAAF82-CF92-437D-8CF9-111A4A26CEE9 Q37715486-412565AA-3A04-4CFC-BCFD-A229DFAE1614 Q50499442-E856DF7C-48F6-4747-8248-5D6F61025CDB

P2860

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

Item

http://www.wikidata.org/entity/Q36082078

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

@ast

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

@en

type

Item

label

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

@ast

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

@en

prefLabel

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

@ast

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

@en

P1476

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

@en

P2093

Janet Barger-Lux

http://www.w3.org/2001/XMLSchema#string

Robert R Recker

http://www.w3.org/2001/XMLSchema#string

P2860

Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.

Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.

Study subjects and ordinary patients.

A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects.

Bone density changes with once weekly risedronate in postmenopausal women.

Bisphosphonates: new indications and methods of administration.

New insights into the molecular mechanisms of action of bisphosphonates.

Is the paradigm shifting?

P304

465-477

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.6.3.465

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15794737

http://www.w3.org/2001/XMLSchema#string

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

about

P2860

P2860

Risedronate for prevention and treatment of osteoporosis in postmenopausal women.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698